siltuximab (sylvant) Report issue

Biologics mAb Orphan Drug FDA Approved FDA First in Class Priority Review FDA

Active Ingredient History

NOW
  • Now
Siltuximab is a chimeric monoclonal antibody. It binds to interleukin-6. Siltuximab has been investigated for the treatment of neoplastic diseases: metastatic renal cell cancer, prostate cancer, other types of cancer, and for Castleman's disease.   Wikipedia

More Chemistry
  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$670.0900 - $2661.7900
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

cclb8 monoclonal antibody | cllb8 | cnto 328 | cnto-328 | cnto 328 monoclonal antibody | monoclonal antibody cnto328 | monoclonal antibody cnto 328 | monoclonal antibody cnto-328 | siltuximab | sylvant

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue